Suvorexant for the Treatment of Insomnia in Adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 27, Issue 9, 2017, Pages 792-795

  Kawabe, Kentaro ^a,b   Horiuchi, Fumie ^a,b   Ochi, Marina ^a,b   Nishimoto, Kayoko ^c   Ueno, Shu Ichi ^b   Oka, Yasunori ^a  

^a EHIME UNIVERSITY HOSPITAL   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Toyokokeiai Hospital   (Japan)

Author keywords

adolescent insomnia; nightmare; orexin antagonist; suvorexant

Indexed keywords

SUVOREXANT; AZEPINE DERIVATIVE; OREXIN RECEPTOR ANTAGONIST; TRIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; ATHENS INSOMNIA SCALE; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MALE; RATING SCALE; SIDE EFFECT; SLEEP QUALITY; TREATMENT OUTCOME; DREAM;

ADOLESCENT; AZEPINES; DREAMS; FEMALE; HUMANS; MALE; OREXIN RECEPTOR ANTAGONISTS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; TRIAZOLES;

EID: 85033784133     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2016.0206     Document Type: Article

References (17)

1. Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD: Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/hyperactivity disorder in children 6 to 17 years of age. Pediatrics 123:770-776, 2009.
2. Chung K, Kan KK, Yeung W: Assessing insomnia in adolescents: Comparison of insomina severity index, athens insomnia scale and sleep quality index. Sleep Med 12:463-470, 2011.
3. Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ,Winrow CJ, Renger JJ: Orexin receptors as therapeutic drug targets. Prog Brain Res 198: 163-188, 2012.
4. Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, Krystal AD, Walsh JK, Benca RM, Rosenberg R, Sangal RB, Budd K, Hutzelmann J, Leibensperger H, Froman S, Lines C, Roth T, Michelson D: Suvorexant in patients with insomnia: Results from two 3-month randomized controlled clinical trials. Biol Psychiatry 79:136-148, 2016.
5. Hysing M, Pallesen S, Stormark KM, Lundervold AJ, Sivertsen B: Sleep patterns and insomnia among adolescents: A populationbased study. J Sleep Res 22:549-556, 2013.
6. Kishi T, Matsunaga S, Iwata N: Suvorexant for primary insomnia: A systematic review and meta-analysis of randomized placebocontrolled trials. PLoS One 10:e0136910, 2015.
7. Maski K, Owens JA: Insomnia, parasomnias, and narcolepsy in children: Clinical features, diagnosis, and management. Lancet Neurol 15:1170-1181, 2016.
8. Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ: Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebocontrolled trial. Lancet Neurol 13:461-471, 2014.
9. Munezawa T,Kaneita Y, Osaki Y, Kanda H,Ohtsu T, Suzuki H,Minowa M, Suzuki K, Higuchi S, Mori J, Ohida T: Nightmare and sleep paralysis among Japanese adolescents: A nationwide representative survey. Sleep Med 12:56-64, 2011.
10. Nakajima S, Inoue U, Sasaki T, Okajima I, Komada Y, Nomura T, Takahashi K: Impact of frequency of nightmares comorbid with insomnia on depression in Japanese rural community residents: A cross-sectional study. Sleep Med 15:371-374, 2014.
11. Okajima I, Nakajima S, Kobayashi M, Inoue Y: Development and validation of the Japanese version of the athens insomnia scale. Psychiatry Clin Neurosci 67:420-425, 2013.
12. Owens JA, Mindell JA: Pediatric insomnia. Peditr Clin North Am 58:555-569, 2011.
13. Sakurai T, Mieda M, Tsujino N: The orexin system: Roles in sleep/ wake regulation. Ann NY Acad Sci 1200:149-161, 2010.
14. Sangal RB, Blumer JL, Lankford DA, Grinnell TA, Huang H: Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder. Pediatrics 134:1095-1103, 2014.
15. Shahid A, Wilkinson K, Marcu S, Shapiro CM: Athens Insomnia Scale (AIS). In STOP, THAT and One Hundred Other Sleep Scales. New York, Springer, 2012, pp. 53-54.
16. Snyder E, Ma J, Svetnik V, Connor KM, Lines C, Michelson D, Herring WJ: Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: Analysis of pooled phase-3 data. Sleep Med 19:93-100, 2016.
17. Soldatos CR, Dikeos, DG, Paparrigopoulos, TJ: The diagnostic validity of the athens insomnia scale. J Psychosom Res 55:263-267, 2003.